One To Watch

Novavax

Company Overview

A US-based biotechnology company pioneering recombinant protein-based vaccines underpinned by its proprietary Matrix-M adjuvant platform, with a lead commercial COVID-19 vaccine and a combination COVID-flu program advancing toward registration. Novavax occupies a distinct niche in the vaccine landscape by offering a protein-based alternative to mRNA and viral vector technologies, which the company argues provides differentiated tolerability and immunogenicity. The company's commercial anchor, Nuvaxovid, received full FDA approval in May 2025 after a prolonged regulatory process, cementing Novavax's position in the US COVID-19 vaccine market. Beyond COVID-19, Novavax is extending its platform into influenza and combination vaccine formats.

Headquarters and Global Presence

Novavax is headquartered in Gaithersburg, Maryland, and maintains a separate R&D and manufacturing entity, Novavax AB, in Sweden, following its 2013 acquisition of Isconova AB. In December 2024, the company sold its Czech Republic manufacturing facility to Novo Nordisk for $200 million, streamlining its global footprint while shoring up its balance sheet.

Founding and History

Novavax was founded in 1987 and spent decades developing its recombinant nanoparticle vaccine technology before the COVID-19 pandemic brought it to global prominence. A pivotal strategic move came in June 2013, when Novavax acquired Swedish firm Isconova AB for $30 million, securing the Matrix-M adjuvant that now defines its platform. The Sanofi co-exclusive licensing agreement signed in June 2024 — followed by a broadened amendment eligible for up to $200 million in milestones — marked the company's most significant commercial partnership to date. Novavax has also navigated considerable financial pressure, executing multiple rounds of workforce reductions including a further 12% headcount cut in mid-2024.

Therapy Areas and Focus

Novavax is focused exclusively on prophylactic vaccines for infectious diseases, with COVID-19 as its primary commercial franchise and influenza as its next major target. The company's rationale centers on the large unmet need among vaccine-hesitant populations who prefer non-mRNA options, as well as tolerability advantages that have been borne out in comparative data. A real-world tolerability study published in April 2026 showed Sanofi's Nuvaxovid outperforming mNEXSPIKE on tolerability, reinforcing Novavax's competitive positioning. Respiratory virus combination vaccines represent the company's near-term pipeline ambition.

Technology Platforms and Modalities

Novavax's core platform combines recombinant protein nanoparticles — engineered to mimic the surface of target viruses — with its proprietary Matrix-M adjuvant, a saponin-based immune stimulator derived from the Quillaja saponaria tree. Matrix-M enhances both cellular and humoral immune responses, enabling lower antigen doses and broader cross-reactive immunity. The adjuvant's commercial appeal has extended beyond Novavax itself: in January 2026, Pfizer entered into a license agreement to use Matrix-M in its own programs, validating the platform's standalone value. Novavax also licensed Matrix-M to SK bioscience, which made an approximately $85 million equity investment in the company in mid-2024.

Key Pipeline and Programs

Nuvaxovid (NVX-CoV2373) is Novavax's approved recombinant, adjuvanted COVID-19 vaccine, built on a stabilized spike protein nanoparticle formulated with Matrix-M. It received full FDA approval in May 2025 — a milestone delayed from an April 1 target date amid regulatory uncertainty — and has been authorized in updated formulations by the FDA, EMA, and MHRA for successive COVID-19 variant strains. The vaccine is now commercialized in partnership with Sanofi under a co-exclusive licensing agreement.

The COVID-19-Influenza Combination (CIC) vaccine is Novavax's lead pipeline asset, combining its COVID-19 antigen with a recombinant influenza antigen, both adjuvanted with Matrix-M. Phase III descriptive data reported in June 2025 showed immune responses in older adults on par with individually approved COVID-19 and influenza vaccines, providing the foundation for a planned registrational study. The program had previously encountered a temporary FDA clinical hold on its IND in October 2024, which was lifted the following month in November 2024, allowing trials to resume.

The standalone recombinant influenza vaccine program also sits within the pipeline, leveraging the same Matrix-M adjuvant framework and positioned as a next-generation alternative to egg-based and existing recombinant flu shots.

Recent Developments

Novavax secured full FDA approval for Nuvaxovid in May 2025, resolving a protracted review process that had drawn scrutiny — including public remarks in April 2025 from HHS Secretary Robert F. Kennedy Jr. questioning the scientific basis of the company's COVID-19 vaccine, which sent shares down more than 20%. In January 2026, Novavax announced a Matrix-M licensing agreement with Pfizer, with shares rising approximately 9% on the news. The broadened Sanofi partnership amendment confirmed Novavax's eligibility for up to $200 million in milestone payments. Phase III data for the CIC combination vaccine, reported June 2025, support advancement to a registrational trial.

Key Personnel

Stanley C. Erck serves as President and Chief Executive Officer, having led Novavax through the COVID-19 pandemic era, the Sanofi partnership, and subsequent commercial restructuring. Gregory Glenn serves as President of Research and Development, co-anchoring the scientific leadership alongside Erck; Glenn has been closely associated with the Matrix-M adjuvant strategy and the company's clinical development programs. Rick Crowley serves as Executive Vice President and Chief Operations Officer, overseeing manufacturing and supply chain operations including the strategic divestiture of the Czech Republic facility.

Strategic Partnerships

The company's most transformative deal is its co-exclusive licensing agreement with Sanofi, signed June 2024, under which Sanofi commercializes Nuvaxovid and Novavax is eligible for up to $200 million in milestone payments under an amended agreement. SK bioscience made an approximately $85 million equity investment in Novavax as part of a strengthened manufacturing and supply partnership. In January 2026, Pfizer licensed Matrix-M for use in its own vaccine programs, generating additional non-dilutive revenue and validating the adjuvant's broader commercial utility. Novavax also settled its longstanding advance purchase agreement dispute with Gavi, the Vaccine Alliance, in June 2024.

FAQ Section

Novavax faced sustained financial pressure — including multiple rounds of layoffs and the sale of its Czech manufacturing plant for $200 million — making a major pharma partner essential for sustained commercial execution. The Sanofi co-exclusive licensing agreement, signed June 2024 and subsequently broadened, gives Novavax access to Sanofi's global vaccine distribution infrastructure while making Novavax eligible for up to $200 million in milestones. The deal allows Novavax to focus internal resources on pipeline development, including the combination COVID-flu program.

Matrix-M is a saponin-based adjuvant derived from Quillaja saponaria bark that stimulates both cellular (T-cell) and humoral (antibody) immune responses, often enabling dose-sparing and broader cross-reactive immunity compared with alum-based adjuvants. Its ability to generate strong immune responses across multiple antigen types makes it attractive beyond Novavax's own programs — Pfizer's January 2026 licensing agreement suggests the adjuvant may be applicable to Pfizer's own vaccine pipeline. Matrix-M is also used by SK bioscience under a separate arrangement, establishing it as a platform asset with revenue potential independent of Nuvaxovid's commercial trajectory.

Unlike Pfizer-BioNTech's and Moderna's mRNA vaccines, Nuvaxovid delivers a pre-formed recombinant spike protein nanoparticle directly to the immune system, a technology with decades of precedent in vaccines such as hepatitis B and HPV shots. This approach is associated with a more conventional tolerability profile, and a real-world study published April 2026 showed Nuvaxovid outperforming mNEXSPIKE on tolerability measures. Novavax targets the segment of the population that is hesitant about newer mRNA technology but willing to accept a protein-based option, representing a structurally distinct commercial niche.

The CIC program uses Novavax's recombinant COVID-19 and influenza antigens co-formulated with Matrix-M adjuvant. Phase III descriptive data reported in June 2025 showed immune responses in older adults comparable to separately approved COVID-19 and influenza vaccines, which Novavax said would inform the design of a future registrational study. The program had previously been placed on FDA clinical hold in October 2024, with the hold lifted the following month, allowing trials to resume without material delay.

Novavax's pipeline is concentrated entirely within infectious disease prophylaxis, with influenza as the principal expansion target alongside COVID-19. The standalone recombinant influenza vaccine candidate leverages the same Matrix-M adjuvant framework and is designed to compete with existing recombinant flu shots on immunogenicity and tolerability. The combination COVID-flu vaccine is the company's near-term pipeline priority, with a registrational study anticipated following positive Phase III descriptive data in mid-2025.

Novavax is a commercial-stage company following full FDA approval of Nuvaxovid in May 2025, with an ongoing seasonal update cycle for its COVID-19 franchise and regulatory approvals in the EU and UK for adapted variant formulations. The CIC combination vaccine is the primary clinical-stage asset, with Phase III descriptive data in hand and a registrational trial design being finalized as of mid-2025. Matrix-M licensing revenues from Pfizer and SK bioscience provide an additional income stream that partially de-risks the company's near-term financial position.

Key watchpoints for Novavax include:

Registrational trial initiation and data readout for the CIC combination COVID-flu vaccine, which represents the company's most material near-term pipeline catalyst.
Nuvaxovid seasonal uptake and market share trends within the US COVID-19 vaccine market, particularly relative to mRNA competitors under the Sanofi commercial partnership.
Regulatory and political risk: RFK Jr.'s April 2025 public questioning of Novavax's scientific approach triggered a 20%-plus share decline, highlighting the company's sensitivity to US health policy sentiment.
Matrix-M licensing revenue growth, particularly from the Pfizer deal signed January 2026, which could become a meaningful non-dilutive revenue contributor.
Balance sheet sustainability following the Czech facility divestiture and prior workforce reductions, with continued reliance on partnership milestone payments.

Want to Update your Company's Profile?